🔗 Share this article The Global Health Body Issues Concern Over Severe Lack of Weight-Loss Injections Less than a tenth of people who could benefit from GLP-1 drugs including Wegovy can access them, warns the WHO as it releases its inaugural advice on the therapies. With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for more widespread and fairer availability to this class of drugs. According to estimates, over two billion are projected to be living with obesity by 2030 unless action is taken. "Our latest guidelines acknowledges that obesity is a lifelong illness that can be managed with holistic and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are significant obstacles to universal availability to the treatments that can aid individuals in losing substantial body mass, notes the agency. GLP-1 Therapy Scarcity Even under the current most optimistic scenario, the manufacturing of such drugs would only suffice for about 100 million people – less than 10% of those who need them, as stated by the WHO. The advice encourages nations and manufacturers to expand access, through approaches such as patent sharing. The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is set to lapse in several countries in 2026. How Obesity Injections Function GLP-1 drugs replicate a biological compound to reduce digestion speed, curb appetite and boost the sense of being full so users eat less. Individuals commonly see weight reduction in the initial weeks of starting on the regular doses. Studies indicates people may see weight return a year later of discontinuing the drug, when their typical hunger return. To be above a healthy weight increases your likelihood for developing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and some malignancies. Excess weight impacts people in every country and was associated with 3.7 million deaths worldwide in 2024, according to the WHO.
Less than a tenth of people who could benefit from GLP-1 drugs including Wegovy can access them, warns the WHO as it releases its inaugural advice on the therapies. With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for more widespread and fairer availability to this class of drugs. According to estimates, over two billion are projected to be living with obesity by 2030 unless action is taken. "Our latest guidelines acknowledges that obesity is a lifelong illness that can be managed with holistic and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are significant obstacles to universal availability to the treatments that can aid individuals in losing substantial body mass, notes the agency. GLP-1 Therapy Scarcity Even under the current most optimistic scenario, the manufacturing of such drugs would only suffice for about 100 million people – less than 10% of those who need them, as stated by the WHO. The advice encourages nations and manufacturers to expand access, through approaches such as patent sharing. The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is set to lapse in several countries in 2026. How Obesity Injections Function GLP-1 drugs replicate a biological compound to reduce digestion speed, curb appetite and boost the sense of being full so users eat less. Individuals commonly see weight reduction in the initial weeks of starting on the regular doses. Studies indicates people may see weight return a year later of discontinuing the drug, when their typical hunger return. To be above a healthy weight increases your likelihood for developing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and some malignancies. Excess weight impacts people in every country and was associated with 3.7 million deaths worldwide in 2024, according to the WHO.